In his editorial comment for the Fall 2026 issue of DDW, Editor Reece Armstrong discusses innovation, investment, and how these come together in the Drug Discovery Innovators & Investors (DDII) event series. In my time with DDW, I’ve learned first-hand about the challenges drug discovery and development… Read More
Phacilitate’s 22nd Advanced Therapies Week (ATW) took place in San Diego on 9-12 February, bringing together industry stakeholders from around the world for to showcase progress in cell and gene therapies (CGT). From manufacturing bottlenecks and regulatory transparency to the rise of in vivo… Read More
As long-term, targeted and sustainable weight loss become the main focus for the obesity drug market, Diana Turner asks whether GLP-1 receptor agonists like semaglutide and tirzepatide can maintain their dominance. With obesity on the rise and a significant area of investment for the big pharma companies,… Read More
New research has revealed that structurally novel neurokinin-1 receptor (NK1R) inhibitors reduce depressive-like behaviour and brain inflammation in mice. For decades, scientists have investigated the NK1R as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after clinical trials of drugs… Read More
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly identified 10 principles for good artificial intelligence (AI) practice in the medicines lifecycle. The principles give broad guidance on AI use in evidence generation and monitoring across… Read More
New research from Paris-based biotech endogene.bio suggests endometriosis is molecularly heterogeneous across patients, lesion sites, and cell types. This molecular heterogeneity has important implications for how endometriosis treatments are studied and developed. Treating the disease as a single entity may help explain why many clinical… Read More
